[1]
|
Gandaglia, G., Abdollah, F., Schiffmann, J., Trudeau, V., Shariat, S.F., Kim, S.P., et al. (2013) Distribution of Metastatic Sites in Patients with Prostate Cancer: A Population-Based Analysis. The Prostate, 74, 210-216. https://doi.org/10.1002/pros.22742
|
[2]
|
Awang, Z.H., Essler, M. and Ahmadzadehfar, H. (2018) Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Current Approaches. Radiation Oncology, 13, Article No. 98. https://doi.org/10.1186/s13014-018-1037-7
|
[3]
|
Kyriakopoulos, C.E., Chen, Y., Carducci, M.A., Liu, G., Jarrard, D.F., Hahn, N.M., et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. Journal of Clinical Oncology, 36, 1080-1087. https://doi.org/10.1200/jco.2017.75.3657
|
[4]
|
Fizazi, K., Foulon, S., Carles, J., Roubaud, G., McDermott, R., Fléchon, A., et al. (2022) Abiraterone Plus Prednisone Added to Androgen Deprivation Therapy and Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer (PEACE-1): A Multicentre, Open-Label, Randomised, Phase 3 Study with a 2×2 Factorial Design. The Lancet, 399, 1695-1707. https://doi.org/10.1016/s0140-6736(22)00367-1
|
[5]
|
Rathkopf, D.E., Smith, M.R., de Bono, J.S., Logothetis, C.J., Shore, N.D., de Souza, P., et al. (2014) Updated Interim Efficacy Analysis and Long-Term Safety of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients without Prior Chemotherapy (COU-AA-302). European Urology, 66, 815-825. https://doi.org/10.1016/j.eururo.2014.02.056
|
[6]
|
Zhang, Z., Wei, M., Mai, L., Li, Y., Wu, J., Huang, H., et al. (2020) Survival Outcomes and Prognostic Analysis Following Greater Cytoreductive Radiotherapy in Patients with Metastatic Prostate Cancer. Frontiers in Oncology, 10, Article 549220. https://doi.org/10.3389/fonc.2020.549220
|
[7]
|
Sweeney, C.J., Martin, A.J., Stockler, M.R., Begbie, S., Chi, K.N., Chowdhury, S., et al. (2021) Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 80, 275-279. https://doi.org/10.1016/j.eururo.2021.05.016
|
[8]
|
Kintzel, P.E., Chase, S.L., Schultz, L.M. and O'Rourke, T.J. (2008) Increased Risk of Metabolic Syndrome, Diabetes Mellitus, and Cardiovascular Disease in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 28, 1511-1522. https://doi.org/10.1592/phco.28.12.1511
|
[9]
|
Grisay, G., Lavaud, P. and Fizazi, K. (2024) Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer. Current Oncology Reports, 26, 488-495. https://doi.org/10.1007/s11912-024-01509-6
|
[10]
|
Basch, E., Autio, K., Ryan, C.J., Mulders, P., Shore, N., Kheoh, T., et al. (2013) Abiraterone Acetate Plus Prednisone versus Prednisone Alone in Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer: Patient-Reported Outcome Results of a Randomised Phase 3 Trial. The Lancet Oncology, 14, 1193-1199. https://doi.org/10.1016/s1470-2045(13)70424-8
|
[11]
|
De Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., et al. (2011) Abiraterone and Increased Survival in Metastatic Prostate Cancer. New England Journal of Medicine, 364, 1995-2005. https://doi.org/10.1056/nejmoa1014618
|
[12]
|
Antonarakis, E.S., Piulats, J.M., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, C.J., et al. (2020) Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. Journal of Clinical Oncology, 38, 395-405. https://doi.org/10.1200/jco.19.01638
|
[13]
|
Zhang, W., Zhang, B. and Chen, X. (2021) Adjuvant Treatment Strategy after Curative Resection for Hepatocellular Carcinoma. Frontiers of Medicine, 15, 155-169. https://doi.org/10.1007/s11684-021-0848-3
|
[14]
|
Yang, J., Zhu, L., Wu, Z. and Wang, Y. (2013) Chinese Herbal Medicines for Induction of Remission in Advanced or Late Gastric Cancer. Cochrane Database of Systematic Reviews, No. 4, CD005096. https://doi.org/10.1002/14651858.cd005096.pub4
|
[15]
|
Wang, L., Ke, J., Wang, C., Li, Y., Wu, G., Ding, Q., et al. (2020) Efficacy and Safety of Banxia Xiexin Decoction, a Blended Traditional Chinese Medicine, as Monotherapy for Patients with Advanced Hepatocellular Carcinoma. Integrative Cancer Therapies, 19, 88-93. https://doi.org/10.1177/1534735420942587
|
[16]
|
Zhai, B., Zhang, N., Han, X., Li, Q., Zhang, M., Chen, X., et al. (2019) Molecular Targets of Β-Elemene, a Herbal Extract Used in Traditional Chinese Medicine, and Its Potential Role in Cancer Therapy: A Review. Biomedicine & Pharmacotherapy, 114, Article 108812. https://doi.org/10.1016/j.biopha.2019.108812
|
[17]
|
Wade, C. and Kyprianou, N. (2018) Profiling Prostate Cancer Therapeutic Resistance. International Journal of Molecular Sciences, 19, Article 904. https://doi.org/10.3390/ijms19030904
|
[18]
|
王苏美, 吴万垠. 中药复方治疗肿瘤的研究进展及存在问题探讨[J]. 中医肿瘤学杂志, 2022, 4(6): 59-65.
|